IsoStent starts US trial of radioactive stent
This article was originally published in Clinica
IsoStent has started US trials of its radioactive Palmaz-Schatz stent. The company hopes that low level radiation will prevent excessive arterial wall remodelling, an unavoidable reaction to the presence of metallic implants on the vessel wall. IRIS, the IsoStent for Restenosis Intervention Study, will follow 30 patients at three US hospitals, but the stents will be made in Germany at the Karlsruhe Research Centre's cyclotron facility.